Business Wire

NOXOPHARM-LIMITED

18.3.2021 13:02:04 CET | Business Wire | Press release

Share
Noxopharm's NOXCOVID Trial Advances to Final Stage

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announced that Veyonda has been approved to move into the second and final stage of the NOXCOVID-1 clinical trial on the advice of the study’s clinicians.

Part 1 of the NOXCOVID-1 trial involved 26 patients and was a dose-escalation arm testing the safety of increasing (400, 600, 800, 1200, 1800 mg) daily Veyonda dosages. The 1800 mg dose was deemed to be sufficiently well tolerated in patients with moderate COVID-19 disease to become the preferred dose. The high tolerance of the drug by patients with very poor lung function provides further evidence of the safety of Veyonda in patients with acute illness.

Noxopharm CEO Dr. Graham Kelly said, “The high potency of Veyonda in blocking cytokine release from damaged tissue in the laboratory meant we were obliged to adopt a very cautious and methodical approach when being used for the first time in patients with poor lung function. We can now be confident that Veyonda, despite its potency, is well tolerated at a dosage we believe will be therapeutic.”

Part 2 of the NOXCOVID-1 trial now is starting to recruit a minimum of 10 and up to 15 patients with moderate-to-severe lung dysfunction. Patients will be treated for up to 14 days with an 1800 mg Veyonda dose each day.

Noxopharm is committed to pursuing its NOXCOVID program for two main reasons: Despite the advent of COVID-19 vaccines, emerging news of new mutant strains of the virus points to a likely ongoing long-term need for effective treatments for COVID-19 patients who go on to develop long-term lung damage and are at high risk of septic shock.

The current pandemic represents a small proportion of patients who die each year from septic shock. Even once the pandemic abates, the need for an effective and safe ongoing treatment for septic shock will remain.

About Noxopharm

Noxopharm is a clinical-stage Australian oncology drug development company with offices in Sydney and New York. The company has a primary focus on the development of Veyonda and is the major shareholder in the nononcology drug development company, Nyrada Inc.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Laserfiche Recognized as a Leader in 2026 Gartner® Magic Quadrant™ for Document Management5.5.2026 16:00:00 CEST | Press release

Laserfiche named a Leader for the second consecutive time based on its Completeness of Vision and Ability to Execute Laserfiche — the leading SaaS provider of intelligent content management — has been positioned as a Leader in the 2026 Magic Quadrant for Document Management. Laserfiche believes this recognition underscores the company’s commitment to empowering organizations to transform complex, operational business processes through AI-powered content management. “It’s incredible to see Laserfiche recognized during the same week as our annual Empower conference, where we announced our latest agentic AI capabilities,” said Thomas Phelps, senior vice president of corporate strategy and chief information officer at Laserfiche. “We believe being positioned as a Leader — and receiving the highest overall rating among 16 vendors in Gartner Peer Insights, with a 4.7 out of 5.0 based on over 1,300 reviews as of April 30, 2026 — reflects our relentless focus on product innovation and deliveri

De’ Longhi and La Marzocco Redefine the Coffee Experience at Milan Design Week 20265.5.2026 15:43:00 CEST | Press release

In the heart of Brera, Milan’s most iconic neighbourhood, the Group celebrated coffee, design, and innovation with two immersive spaces: CASA La Marzocco and The Smallest Coffee Shop at Home with De’ Longhi Milan Design Week annually transforms the city into a global stage for design culture and functional aesthetics, attracting hundreds of thousands of visitors and creatives from around the world to define the year's leading trends. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505367702/en/ Once again, the De’ Longhi Group took the spotlight with activations dedicated to the evolving world of coffee, spanning at-home rituals and out-of-home professional settings. For Milan Design Week 2026, De’ Longhi presented 'The Smallest Coffee Shop at Home,' where the brand reimagined its bestselling machines in the style of cafes around the world. The idea was developed in collaboration with master miniaturist Simon Weisse. The v

Submission Deadline for 5th Cycle of the Mohammed bin Rashid Al Maktoum Global Water Award Extended to 30 September 20265.5.2026 15:41:00 CEST | Press release

In response to requests from a large number of participants, the UAE Water Aid Foundation (Suqia UAE) has extended the submission deadline for the fifth cycle of the Mohammed bin Rashid Al Maktoum Global Water Award to 30 September 2026. The extension aims to enable the widest possible participation from applicants around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505894901/en/ Submission deadline for 5th cycle of the Mohammed bin Rashid Al Maktoum Global Water Award extended to 30 September 2026 (Photo: AETOSWire) Launched by HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and overseen by Suqia UAE under the umbrella of the Mohammed bin Rashid Al Maktoum Global Initiatives, the award supports research and development efforts to develop sustainable solutions to address the global water crisis using renewable energy. It aims to tackle water scarcity

LTM and Uniphore Partner to Scale Domain-Specific AI Across Core Business Processes5.5.2026 15:15:00 CEST | Press release

Uniphore’s Business AI Cloud will power LTM’s BlueVerse™ ecosystem to deliver industry-specific small language models and AI agents for core enterprise workflows Uniphore, the Business AI Company, and LTM, the Business Creativity partner to the world's largest enterprises, today announced a strategic partnership focused on the joint development of industry- and domain-specific AI solutions that combine small language models (SLMs), AI agents, and deep domain expertise. As AI adoption matures, enterprises are shifting to smaller, purpose‑built models and agents for greater precision and control. The partnership brings this approach to core business processes with governance, security, and compliance by design. Uniphore’s Business AI Cloud will power LTM’s BlueVerse™ ecosystem and global delivery, unifying enterprise data, models, and AI agents on a secure, sovereign platform. LTM will drive industry expertise, client implementation, and AI‑led transformation, while Uniphore provides the

QuantWare Raises $178 Million to Build World’s Most Powerful Quantum Processors at an Industrial Scale5.5.2026 15:00:00 CEST | Press release

Largest private round by a dedicated industrial quantum processor company, Intel Capital and In-Q-Tel (IQT) participatingFunds VIO™ technology to deliver world’s most powerful processors for hyperscale quantum compute — and KiloFab, the world’s largest dedicated quantum open architecture fab QuantWare, the leading industrial quantum processor company, today announced a $178 million (€152 million) Series B equity funding round following the announcement of VIO-40K™, a quantum processor architecture for 10,000 qubits, 100x larger than the state of the art today. The company is building KiloFab, the world’s largest dedicated quantum open architecture fab, increasing the company’s production capacity by 20x to meet strong global customer demand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505645970/en/ QuantWare co-founders Matthijs Rijlaarsdam (CEO) and Alessandro Bruno (CTO), pictured outside of QuantWare's KiloFab facil

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye